In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Acasti Pharma (ACST – Research Report). The company’s shares closed yesterday at $2.61.
According to TipRanks, Knickerbocker is a 4-star analyst with an average return of 14.3% and a 62.26% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Ironwood Pharma, and Fennec Pharmaceuticals.
Acasti Pharma has an analyst consensus of Moderate Buy.
See Insiders’ Hot Stocks on TipRanks >>
ACST market cap is currently $23.03M and has a P/E ratio of -0.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acasti Pharma (ACST) Company Description:
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
Read More on ACST:
